loading page

Novel molecular subtype-based precision therapy improves prognosis for lung adenocarcinoma patients
  • +5
  • Ling Zuo,
  • Rui Zhang,
  • Shuting He,
  • Qing Zhang,
  • Yu Shi,
  • Qiang Xu,
  • Feng Li,
  • Ling Gai
Shuting He
Author Profile
Qing Zhang
Author Profile
Ling Gai

Corresponding Author:[email protected]

Author Profile

Abstract

Lung adenocarcinoma is a malignancy with a high global incidence and cancer-related mortality rate.The 5-year survival rate is low. This study aimed to improve the prognosis of LUAD patients. LUAD RNA sequencing data obtained from online database.Weighted gene co-expression network analysis combined with univariate and multifactorial COX analysis was used to identify hub prognostic genes. Based on these genes, pam clustering classified LUAD into two subtypes. The ESTIMATE, Immunophenoscore, and Microenvironment Cell Populations-counter algorithm were applied to determine the microenvironmental purity and immune. Genomic enrichment analysis was performed to analyze the function. Mutational difference was also explored. The effects of cisplatin and FASNi on gene expression were examined by RT-PCR.The results showed LUAD patients could be divided into two subtypes. The survival rate of patients in cluster 2 was signifcantly higher than that in cluster 1. Patients in cluster 2 had more immune cell infiltration, higher microenvironmental component, and higher rate of EGFR mutations. Patients in cluster 1 had more fibroblast infiltration and high rate of NTRK3 mutations. Functional analysis suggested cluster 1 was associated with Nucleotide sequence repair, while cluster 2 mainly related to lipid metabolism and angiogenic pathways. RT-PCR indicated that cluster1-related model genes were associated with cisplatin, cluster2-related genes were associated with EGFR-targeted therapy and lipid metabolism inhibitors.This study showed patients in cluster 1 may benefit from anti-Nucleotide repair therapies such as platinum, radiotherapy, targeting fibroblasts, and targeting NTRK3, while patients in cluster 2 benefit from immunotherapy, anti-angiogenic,targeting lipid metabolism, and targeting EGFR therapy.